<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11379605</article-id><article-id pub-id-type="pmc">2363881</article-id><article-id pub-id-type="pii">6691623</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1623</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Adjuvant interferon alpha 2b in high risk melanoma &#x02013; the Scottish study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cameron</surname><given-names>D A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cornbleet</surname><given-names>M C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mackie</surname><given-names>R M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hunter</surname><given-names>J A A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gore</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hancock</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Smyth</surname><given-names>J F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><collab>on behalf of the Scottish Melanoma Group</collab></contrib></contrib-group><aff id="aff1"><label>1</label>Western General Hospital, Crewe Road South, Edinburgh</aff><aff id="aff2"><label>2</label>Western Infirmary, Dumbarton Road, Glasgow</aff><aff id="aff3"><label>3</label>Royal Infirmary, Lauriston Place, Edinburgh</aff><aff id="aff4"><label>4</label>Royal Marsden Hospital, Downs Road, Surron Surrey</aff><aff id="aff5"><label>5</label>Weston Park Hospital, Whitham Road, Sheffield, UK</aff><pub-date pub-type="ppub"><month>05</month><year>2001</year></pub-date><volume>84</volume><issue>9</issue><fpage>1146</fpage><lpage>1149</lpage><history><date date-type="received"><day>19</day><month>07</month><year>2000</year></date><date date-type="rev-recd"><day>08</day><month>11</month><year>2000</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>In 1989, the Scottish melanoma group initiated a randomized trial, comparing observation alone with 6 months' therapy with low dose interferon &#x003b1; (given subcutaneously 3 MU day<sup>&#x02013;1</sup>, thrice weekly), for patients with primary melanomas of at least 3&#x02008;mm Breslow thickness, or with evidence of regional node involvement. The trial was closed in 1993 with only 95 eligible patients randomized. There were no toxic deaths, and no patient failed to complete the treatment for reasons of toxicity. 6 months' treatment with low-dose interferon-&#x003b1; resulted in a statistically significant improved disease-free survival for up to 24 months after randomization (<italic>P</italic>&#x0003c; 0.05). However, at a median follow-up of over 6 years, although there was an apparent improvement in disease-free survival (from 9 to 22 months), and overall survival (from 27 to 39 months), consistent with larger studies powered to detect such differences, these differences were not statistically significant. The data therefore suggest that 6 months of low-dose interferon is active, and confirm the importance of the large randomized studies, such as the UKCCCR AIM-High and EORTC trials, that seek to confirm a possible survival advantage for low or intermediate dose interferon. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>adjuvant</kwd><kwd>interferon</kwd><kwd>melanoma</kwd><kwd>Scottish trial</kwd></kwd-group></article-meta></front></article>


